Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

IP Group to gain from life sciences buyouts

Published 20/12/2024, 07:08
IPO
-

LONDON - IP Group plc (LSE: LON:IPO), an investor in innovative science and technology companies, has announced that two of its life sciences portfolio companies have received cash offers, which are expected to yield significant proceeds for the group. Intelligent Ultrasound Group plc, with IP Group holding a 20.8% interest, has been valued at approximately £45.2 million following a cash offer from Surgical Science Sweden AB. This transaction is anticipated to result in IP Group receiving around £8.8 million, doubling the value from its last reported net asset value (NAV) as of June 30, 2024.

Similarly, Abliva AB, in which IP Group has a 9.5% stake, received a buyout offer from Pharming Technologies BV, valuing Abliva at roughly SEK 725.3 million (equivalent to £52.4 million). This deal is expected to provide IP Group with £5 million, representing an uplift in carrying value of £3.7 million or 284% since the last NAV report.

Completion of both deals is contingent upon customary conditions and shareholder approval. The company plans to allocate approximately 20% of the proceeds from these sales to enhance its share buyback program in 2025, adhering to its capital allocation policy.

Greg Smith, Chief Executive of IP Group, expressed pleasure at the continued interest in the Group's life sciences portfolio, highlighting the successful sale of Kynos Therapeutics earlier in October. He extended congratulations to the teams at Intelligent Ultrasound and Abliva for their achievements.

The forthcoming cash infusions are part of IP Group's broader strategy to capitalize on its investments in high-potential companies within the life sciences sector. The information disclosed is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.